Welcome to
George Medicines
Multiple drugs are increasingly being prescribed to adequately control conditions such as hypertension, cardiovascular disease and type 2 diabetes. This can be complicated for patients and costly for health systems. At George Medicines we are using our drug development expertise and the latest formulation approaches to combine existing medicines into novel single-pill therapies with the potential to bring significant improvements in clinical outcomes and adherence.
About Us
George Medicines is a late-stage drug development company focused on improving the management of non-communicable diseases with innovative single-pill combinations of existing medicines. By combining best-in-class molecules from existing medicines in proprietary low-dose formulations, George Medicines is aiming to develop innovative treatments with the potential to be more efficacious, safer and more accessible than currently available treatment options.
Our Approach
George Medicines is a venture-backed spin-out company from The George Institute for Global Health, one of the world’s leading medical research institutes in non-communicable diseases. Our differentiated business model avoids the early, high-risk stages of drug discovery and development by formulating established drugs into innovative, single-pill combinations using proprietary technology, which reduces time-to-market and brings a higher probability of success while requiring less capital investment than is usual in the industry.
Pipeline
We are building a strong and diversified proprietary pipeline of innovative single-pill combination therapies in late-stage development, targeting some of the leading causes of death in both developed and developing countries, including hypertension, cardiovascular disease and type 2 diabetes.
Partners
Our strategy is to advance our late-stage pipeline through the final stages of development and to secure approval from global regulators. We work alongside appropriate partners to commercialise our therapies across the developed and developing world where our medicines can reduce the burden on health systems and have the biggest positive social impact
Latest News
Chairman’s Statement
“George Medicines is uniquely positioned to change the lives of the more than 2 billion people around the world suffering from non-communicable diseases with our novel single-pill therapies. By targeting underserved populations in established and emerging markets, we are making better medicines for all. And never was it more urgent, as the pandemic has highlighted weaknesses and inequalities in health systems globally”
Part of a mission to deliver affordable and scalable treatments and technologies
George Medicines is one of George Health’s four businesses, created to commercialise medicines and technologies that leverage the George Institute’s late-stage clinical research for chronic disease.
VIEW WEBSITE +
George
Health
Science, service, solutions. A leading CRO in Asia-Pacific with global capabilities
George
Clinical
Science, service, solutions. A leading CRO in Asia-Pacific with global capabilities
